PHASE I STUDY TO EVALUATE SAFETY OF DERMAVIR, A HIV VACCINE, IN HIV-I SUBJECTS U
$7,548M01FY2004RRNIH
University Of California Davis, Davis CA
Investigators
Linked publications & trials
Paper 27392827Paper 26898803Paper 26639357Paper 25003624Paper 24709689Paper 24371799Paper 23721964Paper 23023585Paper 21295742Paper 21264979Paper 20605499Paper 20214417Paper 20206985Paper 20142790Paper 19512949Paper 19355810Paper 18939997Paper 18580806Paper 18390991Paper 18384705Paper 18255343Paper 18202591Paper 18046190Paper 17543850Paper 17344488Paper 17172560Paper 17110238Paper 17019599Paper 16888319Paper 16774477Paper 16709953Paper 16600927Paper 16495513Paper 16317063Paper 16215393Paper 16002813
View original record on NIH RePORTER →